RxDoctor Payments Data

Sara Healy, MD

Endocrinology, Diabetes & Metabolism · Augusta, GANPI 1457677833

Payments from drug & device makers

$361in general payments, 2019–2025

Across 21 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$77
  • Insulet Corporation$55
  • Tandem Diabetes Care, Inc.$33
  • Aurinia Pharma U.S., Inc.$27
  • Amgen$22
  • BD$21
  • plus $125 from 8 others

What the payments were for

  • Food & beverage$361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$361 in reported general payments places this provider in the 15th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$17,424
Medicare patients
104
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide146$168,559
JardianceEmpagliflozin58$60,585
TrulicityDulaglutide36$46,330
MounjaroTirzepatide31$41,913
Tresiba Flextouch U-200Insulin Degludec30$40,089
Fiasp FlextouchInsulin Aspart (Niacinamide)30$35,527
Novolog FlexpenInsulin Aspart58$14,702
JanuviaSitagliptin Phosphate11$12,994
Tresiba Flextouch U-100Insulin Degludec16$10,836
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$10,150
Repatha SureclickEvolocumab13$7,179
HumalogInsulin Lispro18$6,958
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$6,492
Nano 2nd Gen Pen NeedlePen Needle, Diabetic39$6,293
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$5,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$20$49278 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

Other endocrinology, diabetes & metabolism in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →